Sparton Corporation (NYSE: SPA), a supplier of complex and reliable electronic and electro-mechanical products, sub-assemblies and related services to the highly regulated Medical, Defense & Security, and Aerospace markets announces that on August 6, 2010 its wholly owned subsidiary, Sparton Medical Systems Colorado, LLC, completed its previously announced acquisition of certain assets related to the contract manufacturing business of Delphi Medical Systems, LLC ("Delphi Medical"). The all-cash transaction is valued at approximately $8.0 million.
“This acquisition marks our company's developmental shift from preservation and turnaround mode to a focus on strategic growth. In selecting Delphi Medical, we identified synergistic operational opportunities across all of Sparton's existing business units and we believe this is an appropriate inaugural acquisition as we implement our growth strategy.”
The acquisition of certain assets of Delphi Medical, located near Denver, Colorado, provides Sparton with immediate entry into the Therapeutic Device Market, and is expected to add $32 million in projected annual revenue from a new and diversified customer base. Delphi Medical primarily manufactures OEM medical devices including blood separation equipment, spinal surgery products and 3-D eye mapping devices. The company also provides engineering and manufacturing support to a market-leading environmental sensor company whose markets include meteorology, weather critical operations and controlled environment applications.
Cary Wood, President & CEO of Sparton stated, "This acquisition marks our company's developmental shift from preservation and turnaround mode to a focus on strategic growth. In selecting Delphi Medical, we identified synergistic operational opportunities across all of Sparton's existing business units and we believe this is an appropriate inaugural acquisition as we implement our growth strategy.
"The addition of this business meets the criteria of our growth strategy by providing expansion into the therapeutic device market, diversifying our customer base and expanding our geographic reach into the western United States. We expect the integration of Delphi Medical's operations will also strengthen our business development efforts, adding West Coast coverage and bringing existing manufacturing representative agreements.
"Sparton has worked hard during the last year and a half to embrace operational and financial improvements focused on Sparton's return to profitability. We look forward to the timely integration of Delphi Medical and expect this new addition to provide increased shareholder value," Mr. Wood concluded.
Innovative bacteria-based therapy shows promise against cancer